Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

pembrolizumab 8fludarabine 4Cyclophosphamide 4amatuximab 3Thiotepa 3Nivolumab 3Ipilimumab 3Hyperthermic Intraperitoneal Chemotherapy 3Filgrastim 3Carboplatin 3budigalimab 2belinostat 2SS1(dsFv)PE38 2Platinum 2Peripheral Blood Stem Cell Transplantation 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2venetoclax 1talazoparib 1sodium thiosulfate 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine phosphate 1epacadostat 1durvalumab 1bosutinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × BAY 1895344 × Other solid neoplasm × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡